Concepts (59)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spike Glycoprotein, Coronavirus | 1 | 2024 | 40 | 0.960 |
Why?
|
| Ecology | 1 | 2023 | 74 | 0.890 |
Why?
|
| India | 6 | 2024 | 120 | 0.780 |
Why?
|
| Poverty Areas | 1 | 2020 | 37 | 0.760 |
Why?
|
| Seroepidemiologic Studies | 5 | 2024 | 55 | 0.750 |
Why?
|
| Drug Approval | 2 | 2012 | 62 | 0.730 |
Why?
|
| Residence Characteristics | 1 | 2020 | 197 | 0.680 |
Why?
|
| Health Status Disparities | 1 | 2020 | 170 | 0.660 |
Why?
|
| Placebo Effect | 2 | 2008 | 31 | 0.650 |
Why?
|
| Biological Evolution | 1 | 2023 | 919 | 0.540 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 1169 | 0.510 |
Why?
|
| Cetirizine | 1 | 2013 | 12 | 0.470 |
Why?
|
| Television | 1 | 2013 | 29 | 0.470 |
Why?
|
| Loratadine | 1 | 2013 | 21 | 0.470 |
Why?
|
| Hypersensitivity | 1 | 2013 | 154 | 0.410 |
Why?
|
| Legislation, Drug | 1 | 2008 | 7 | 0.340 |
Why?
|
| Vaccination | 3 | 2024 | 254 | 0.310 |
Why?
|
| Antibodies, Viral | 2 | 2024 | 293 | 0.270 |
Why?
|
| Immunity, Humoral | 1 | 2024 | 67 | 0.230 |
Why?
|
| Antibodies, Neutralizing | 1 | 2024 | 112 | 0.230 |
Why?
|
| Immunity, Cellular | 1 | 2024 | 177 | 0.230 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 508 | 0.230 |
Why?
|
| Peer Group | 1 | 2023 | 72 | 0.220 |
Why?
|
| Humans | 12 | 2024 | 86643 | 0.200 |
Why?
|
| Vaccines | 1 | 2022 | 80 | 0.190 |
Why?
|
| Exercise | 1 | 2023 | 315 | 0.180 |
Why?
|
| United States Food and Drug Administration | 2 | 2012 | 127 | 0.180 |
Why?
|
| Adult | 5 | 2023 | 25648 | 0.170 |
Why?
|
| Prevalence | 1 | 2020 | 1239 | 0.140 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1621 | 0.140 |
Why?
|
| Young Adult | 3 | 2021 | 5976 | 0.140 |
Why?
|
| Adolescent | 3 | 2021 | 8981 | 0.130 |
Why?
|
| Middle Aged | 3 | 2021 | 25028 | 0.120 |
Why?
|
| Histamine H1 Antagonists, Non-Sedating | 1 | 2013 | 13 | 0.120 |
Why?
|
| Child | 2 | 2021 | 6927 | 0.110 |
Why?
|
| Male | 4 | 2021 | 40965 | 0.090 |
Why?
|
| Fraud | 1 | 2008 | 6 | 0.090 |
Why?
|
| Female | 4 | 2021 | 44532 | 0.090 |
Why?
|
| Consumer Advocacy | 1 | 2008 | 10 | 0.090 |
Why?
|
| Liability, Legal | 1 | 2008 | 32 | 0.080 |
Why?
|
| Malpractice | 1 | 2008 | 57 | 0.080 |
Why?
|
| Bias | 1 | 2008 | 127 | 0.080 |
Why?
|
| United States | 2 | 2012 | 6672 | 0.080 |
Why?
|
| Caffeine | 1 | 2008 | 81 | 0.070 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 399 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 3640 | 0.070 |
Why?
|
| Informed Consent | 1 | 2008 | 266 | 0.070 |
Why?
|
| Heart Rate | 1 | 2008 | 492 | 0.070 |
Why?
|
| Central Nervous System Stimulants | 1 | 2008 | 216 | 0.060 |
Why?
|
| Models, Neurological | 1 | 2008 | 405 | 0.060 |
Why?
|
| Aged | 1 | 2021 | 18415 | 0.060 |
Why?
|
| Time Factors | 1 | 2013 | 5210 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2008 | 1143 | 0.050 |
Why?
|
| Rural Health | 1 | 2021 | 20 | 0.050 |
Why?
|
| Urban Health | 1 | 2021 | 55 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2013 | 7993 | 0.050 |
Why?
|
| Health Surveys | 1 | 2021 | 239 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 376 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 454 | 0.040 |
Why?
|